1. prisoner 2. unable to randomize within 14 days after onset of acute respiratory infection symptoms 3. patient, legal representative, or physician not committed to full support (exception: a patient who will receive all supportive care except for attempts at resuscitation from cardiac arrest will not be excluded.) 4. inability to be contacted on day 29-36 for clinical outcome assessment 5. receipt of any sars-cov-2 passive immunity therapy, such as convalescent plasma, monoclonal antibodies, or pooled immunoglobulin, in the past 30 days 6. contraindications to transfusion or history of prior reactions to transfused blood products 7. plan for hospital discharge within 24 hours of enrollment 8. previous enrollment in this trial 9. previous laboratory-confirmed sars-cov-2 infection before the current illness 10. enrollment in another clinical trial evaluating monoclonal antibodies, convalescent plasma, or another passive immunity therapy 11. prior receipt of sars-cov-2 vaccine

1. prisoner 2. unable to randomize within 14 days after onset of acute respiratory infection symptoms 3. patient, legal representative, or physician not committed to full support (exception: a patient who will receive all supportive care except for attempts at resuscitation from cardiac arrest will not be excluded.) 4. inability to be contacted on day 29-36 for clinical outcome assessment 5. receipt of any sars-cov-2 passive immunity therapy, such as convalescent plasma, monoclonal antibodies, or pooled immunoglobulin, in the past 30 days 6. contraindications to transfusion or history of prior reactions to transfused blood products 7. plan for hospital discharge within 24 hours of enrollment 8. previous enrollment in this trial 9. previous laboratory-confirmed sars-cov-2 infection before the current illness 10. enrollment in another clinical trial evaluating monoclonal antibodies, convalescent plasma, or another passive immunity therapy 11. prior receipt of sars-cov-2 vaccine

prisoner unable to randomize within 14 days after onset of acute respiratory infection symptoms patient, legal representative, or physician not committed to full support (exception: a patient who will receive all supportive care except for attempts at resuscitation from cardiac arrest will not be excluded.) inability to be contacted on day 29-36 for clinical outcome assessment receipt of any sars-cov-2 passive immunity therapy, such as convalescent plasma, monoclonal antibodies, or pooled immunoglobulin, in the past 30 days contraindications to transfusion or history of prior reactions to transfused blood products plan for hospital discharge within 24 hours of enrollment previous enrollment in this trial previous laboratory-confirmed sars-cov-2 infection before the current illness enrollment in another clinical trial evaluating monoclonal antibodies, convalescent plasma, or another passive immunity therapy prior receipt of sars-cov-2 vaccine

prisoner unable to randomize within 14 days after onset of acute respiratory infection symptoms patient, legal representative, or physician not committed to full support (exception: a patient who will receive all supportive care except for attempts at resuscitation from cardiac arrest will not be excluded.) inability to be contacted on day 29-36 for clinical outcome assessment receipt of any sars-cov-2 passive immunity therapy, such as convalescent plasma, monoclonal antibodies, or pooled immunoglobulin, in the past 30 days contraindications to transfusion or history of prior reactions to transfused blood products plan for hospital discharge within 24 hours of enrollment previous enrollment in this trial previous laboratory-confirmed sars-cov-2 infection before the current illness enrollment in another clinical trial evaluating monoclonal antibodies, convalescent plasma, or another passive immunity therapy prior receipt of sars-cov-2 vaccine

1. prisoner 2. unable to randomize within 14 days after onset of acute respiratory infection symptoms 3. patient, legal representative, or physician not committed to full support (exception: a patient who will receive all supportive care except for attempts at resuscitation from cardiac arrest will not be excluded.) 4. inability to be contacted on day 29-36 for clinical outcome assessment 5. receipt of any sars-cov-2 passive immunity therapy, such as convalescent plasma, monoclonal antibodies, or pooled immunoglobulin, in the past 30 days 6. contraindications to transfusion or history of prior reactions to transfused blood products 7. plan for hospital discharge within 24 hours of enrollment 8. previous enrollment in this trial 9. previous laboratory-confirmed sars-cov-2 infection before the current illness 10. enrollment in another clinical trial evaluating monoclonal antibodies, convalescent plasma, or another passive immunity therapy 11. prior receipt of sars-cov-2 vaccine

1. prisoner 2. unable to randomize within 14 days after onset of acute respiratory infection symptoms 3. patient, legal representative, or physician not committed to full support (exception: a patient who will receive all supportive care except for attempts at resuscitation from cardiac arrest will not be excluded.) 4. inability to be contacted on day 29-36 for clinical outcome assessment 5. receipt of any sars-cov-2 passive immunity therapy, such as convalescent plasma, monoclonal antibodies, or pooled immunoglobulin, in the past 30 days 6. contraindications to transfusion or history of prior reactions to transfused blood products 7. plan for hospital discharge within 24 hours of enrollment 8. previous enrollment in this trial 9. previous laboratory-confirmed sars-cov-2 infection before the current illness 10. enrollment in another clinical trial evaluating monoclonal antibodies, convalescent plasma, or another passive immunity therapy 11. prior receipt of sars-cov-2 vaccine

prisoner unable to randomize within 14 days after onset of acute respiratory infection symptoms patient, legal representative, or physician not committed to full support (exception: a patient who will receive all supportive care except for attempts at resuscitation from cardiac arrest will not be excluded.) inability to be contacted on day 29-36 for clinical outcome assessment receipt of any sars-cov-2 passive immunity therapy, such as convalescent plasma, monoclonal antibodies, or pooled immunoglobulin, in the past 30 days contraindications to transfusion or history of prior reactions to transfused blood products plan for hospital discharge within 24 hours of enrollment previous enrollment in this trial previous laboratory-confirmed sars-cov-2 infection before the current illness enrollment in another clinical trial evaluating monoclonal antibodies, convalescent plasma, or another passive immunity therapy prior receipt of sars-cov-2 vaccine

prisoner unable to randomize within 14 days after onset of acute respiratory infection symptoms patient, legal representative, or physician not committed to full support (exception: a patient who will receive all supportive care except for attempts at resuscitation from cardiac arrest will not be excluded.) inability to be contacted on day 29-36 for clinical outcome assessment receipt of any sars-cov-2 passive immunity therapy, such as convalescent plasma, monoclonal antibodies, or pooled immunoglobulin, in the past 30 days contraindications to transfusion or history of prior reactions to transfused blood products plan for hospital discharge within 24 hours of enrollment previous enrollment in this trial previous laboratory-confirmed sars-cov-2 infection before the current illness enrollment in another clinical trial evaluating monoclonal antibodies, convalescent plasma, or another passive immunity therapy prior receipt of sars-cov-2 vaccine

1. prisoner 2. unable to randomize within 14 days after onset of acute respiratory infection symptoms 3. patient, legal representative, or physician not committed to full support (exception: a patient who will receive all supportive care except for attempts at resuscitation from cardiac arrest will not be excluded.) 4. inability to be contacted on day 29-36 for clinical outcome assessment 5. receipt of any sars-cov-2 passive immunity therapy, such as convalescent plasma, monoclonal antibodies, or pooled immunoglobulin, in the past 30 days 6. contraindications to transfusion or history of prior reactions to transfused blood products 7. plan for hospital discharge within 24 hours of enrollment 8. previous enrollment in this trial 9. previous laboratory-confirmed sars-cov-2 infection before the current illness 10. enrollment in another clinical trial evaluating monoclonal antibodies, convalescent plasma, or another passive immunity therapy 11. prior receipt of sars-cov-2 vaccine

1. prisoner 2. unable to randomize within 14 days after onset of acute respiratory infection symptoms 3. patient, legal representative, or physician not committed to full support (exception: a patient who will receive all supportive care except for attempts at resuscitation from cardiac arrest will not be excluded.) 4. inability to be contacted on day 29-36 for clinical outcome assessment 5. receipt of any sars-cov-2 passive immunity therapy, such as convalescent plasma, monoclonal antibodies, or pooled immunoglobulin, in the past 30 days 6. contraindications to transfusion or history of prior reactions to transfused blood products 7. plan for hospital discharge within 24 hours of enrollment 8. previous enrollment in this trial 9. previous laboratory-confirmed sars-cov-2 infection before the current illness 10. enrollment in another clinical trial evaluating monoclonal antibodies, convalescent plasma, or another passive immunity therapy 11. prior receipt of sars-cov-2 vaccine

1. prisoner 2. unable to randomize within 14 days after onset of acute respiratory infection symptoms 3. patient, legal representative, or physician not committed to full support (exception: a patient who will receive all supportive care except for attempts at resuscitation from cardiac arrest will not be excluded.) 4. inability to be contacted on day 29-36 for clinical outcome assessment 5. receipt of covid-19 convalescent plasma or pooled immunoglobulin in the past 30 days 6. contraindications to transfusion or history of prior reactions to transfused blood products 7. plan for hospital discharge within 24 hours of enrollment 8. previous enrollment in this trial 9. enrollment in another clinical trial evaluating monoclonal antibodies, convalescent plasma, or another passive immunity therapy

1. prisoner 2. unable to randomize within 14 days after onset of acute respiratory infection symptoms 3. patient, legal representative, or physician not committed to full support (exception: a patient who will receive all supportive care except for attempts at resuscitation from cardiac arrest will not be excluded.) 4. inability to be contacted on day 29-36 for clinical outcome assessment 5. receipt of covid-19 convalescent plasma or pooled immunoglobulin in the past 30 days 6. contraindications to transfusion or history of prior reactions to transfused blood products 7. plan for hospital discharge within 24 hours of enrollment 8. previous enrollment in this trial 9. enrollment in another clinical trial evaluating monoclonal antibodies, convalescent plasma, or another passive immunity therapy

- prisoner - unable to randomize within 14 days after onset of acute respiratory infection symptoms - unable to randomize within 48 hours after hospital arrival - inability to be contacted on day 29-36 for clinical outcome assessment - receipt of pooled immunoglobulin in the past 30 days - contraindications to transfusion or history of prior reactions to transfusion blood products - previous enrollment in this trial

- prisoner - unable to randomize within 14 days after onset of acute respiratory infection symptoms - unable to randomize within 48 hours after hospital arrival - inability to be contacted on day 29-36 for clinical outcome assessment - receipt of pooled immunoglobulin in the past 30 days - contraindications to transfusion or history of prior reactions to transfusion blood products - previous enrollment in this trial